摘要
应用免疫组织化学LSAB法,对40例乳腺癌的P53抗癌基因(P53)、雌激素受体(ER)、孕激素受体(PR)进行了检测,结果显示:P53阳性24例(60%),ER阳性20例(50%),PR阳性15例(37.5%),其中三项均阳性者7例,而P53与ER均阳性者14例,P53与PR均阳性者11例。结果表明:乳腺癌中P53阳性率高于良性乳腺肿瘤,差异显著(P<0.01),ER阳性率随患者年龄增大而升高;50岁以上患者阳性率明显高于50岁以下者;而P53、PR的表达与年龄无关。本组研究表明,ER、PR阳性患者采用手术治疗和术后放疗、化疗再增加内分泌治疗,可使患者5年、10年生存率明显提高,而P53阳性、ER阴性的患者无明显疗效。
A LSAB immunohistochemical method was performed on 40 cases of human breast cancer to detect P 53 antioncogene(P 53 ), estrogen receptor(ER) and progestogen receptor(PR).Results showed that there were 24(60%) P 53 ,20(50%) ER ,and 15(37.5%) PR positive cases among all cancers examined.In the P 53 positive cases,there were 7 cases both ER and PR positive;14 cases ER positive;and 11 PR positive.The result suggested that there be a significant difference in P 53 positive rates between malignant and benign breast tumors.ER positive rate increases with one′s ageing,especially those over fifty.There is no marked relationship between patient′s age and the expression of P 53 ,PR.The author suggests that if ER ,and PR positive cases be treated by a combination of surgery,radiotherapy,chemotherapy and additional endocrinotherapy,their five year or ten year survival rate must be going up markedly.However,patients with P 53 positive and ER negative reactions have no hope of marked curative effect.
出处
《山西医药杂志》
CAS
1997年第2期123-125,共3页
Shanxi Medical Journal
关键词
乳腺癌
P53基因
雌激素
孕激素
受体
治疗
预后
breast cancer P
53 antioncogene estrogen receptor progestogen receptor